Advertisement


Laurence Albiges, MD, PhD, on Renal Cell Carcinoma: New Phase II Data on Cabozantinib and Checkpoint Inhibitor Therapy

2023 ASCO Genitourinary Cancers Symposium

Advertisement

Laurence Albiges, MD, PhD, of France’s Gustave Roussy Cancer Centre, discusses interim results from the CaboPoint study, which evaluated cabozantinib as second-line treatment in patients with unresectable, locally advanced or metastatic renal cell carcinoma with a clear cell component. Disease in the study participants had progressed after prior treatment with ipilimumab and nivolumab in combination or combined with VEGF-targeted therapy. (Abstract 606).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Standard of care for renal cell carcinoma is combination therapy, meaning in patients with clear cell RCC, we have access either to a combination of doublet IO, namely nivolumab plus ipilimumab, or a combination of VGF targeting plus an immune checkpoint, such as axitinib, pembrolizumab, cabozantinib, nivolumab, or lenvatinib, pembrolizumab as well. Right now, what we don't know is what we should do in patient who failed first line therapy, meaning having disease progression under first line therapy. The purpose of CaboPoint study that has been presented at ASCO GU meeting 2023 is to investigate cabozantinib activity after first line combination failure. The study has been designed to assess activity and safety of cabozantinib single agent, so it's a Phase II, a non-randomized Phase II with two cohorts. Cohort A, patient who had failed nivolumab plus ipilimumab and Cohort B, patient who had failed VGF plus TKI regimen. What has been presented at this meeting is the interim analysis of CaboPoint study. This pre-plan analysis was designed to be performed when 80% of cohort bay had been enrolled and for which we had more than three months follow-up. So 88 patients are part of this analysis. Primary endpoint is response rate, and the key message is that with cabozantinib single agent, we are able to reach a response rate of almost 30% divided in 32% in Cohort A and 25% in Cohort B. Of course, there was no new safety signal with cabozantinib single agent. This study is important because it is the first time we have cabozantinib pure second-line data after a doublet with an IO-based first-line regimen. What is needed now is to know with further follow-up the PFS and overall survival within this study, and that will be the subject of further analysis. What we also would like to know, is there anything we should add on top of cabozantinib? And that's the topic of the CONTACT-03 study that is still pending to know if there is an added value of sustained PD-L1 inhibition, for instance. So to summarize, CaboPoint is the first prospective study of cabozantinib as a pure second line after combination therapy in first line, showing you response rates of 30% for a single-agent TKI. And it means our patient, including those who did progress under first line, should be offered a second line therapy.

Related Videos

Prostate Cancer

Daniel P. Petrylak, MD, on Prostate Cancer: Latest Data on Pembrolizumab Plus Docetaxel

Daniel P. Petrylak, MD, of the Yale Cancer Center, discusses phase III findings from the KEYNOTE-921 study, which was designed to assess the combination of pembrolizumab and docetaxel in the treatment of patients with metastatic castration-resistant prostate cancer. They had not received chemotherapy, but their disease progressed on the next-generation hormonal agent, or they could not tolerate the agent. (Abstract 19).

Prostate Cancer

Alan H. Bryce, MD, on Prostate Cancer: Phase III Results on Rucaparib, Docetaxel, and Androgen Pathway Inhibitor Therapy

Alan H. Bryce, MD, of the Mayo Clinic, discusses the final results of the primary endpoint of rPFS and interim results on overall survival among patients with chemotherapy-naive metastatic castration-resistant prostate cancer. The data showed that rucaparib improved radiographic progression-free survival compared with either docetaxel or abiraterone and enzalutamide in disease with BRCA1/2 alterations. (Abstract 18).

Prostate Cancer

Neeraj Agarwal, MD, on Prostate Cancer: New Data on Talazoparib and Enzalutamide

Neeraj Agarwal, MD, of the Huntsman Cancer Institute, University of Utah, discusses phase III results from the TALAPRO-2 study, which suggested an improvement in radiographic progression-free survival with the combination of talazoparib and enzalutamide over standard-of-care enzalutamide alone as first-line treatment in patients with metastatic castration-resistant prostate cancer. The improvement was seen regardless of homologous recombination repair gene mutations. The combination regimen delayed the time to chemotherapy and worsening in global health status and quality of life. (Abstract LBA17).

Prostate Cancer

Scott T. Tagawa, MD, on Prostate Cancer: Phase II Results on Ketoconazole, Hydrocortisone, and an Anti-PSMA Antibody

Scott T. Tagawa, MD, of Weill Cornell Medicine, NewYork-Presbyterian Hospital, discusses study results showing that, the anti-PSMA (prostate-specific membrane antigen) monoclonal antibody J591 with ketoconazole and hydrocortisone, when radiolabeled with lutetium-177, leads to improved 18-month metastasis-free survival vs radiolabeling with indium-111 in patients with nonmetastatic (M0) castration-resistant prostate cancer. This supports the development of anti-PSMA radioimmunotherapy, although the optimal radionuclide and targeting agent are unknown. (Abstract LBA21).

Bladder Cancer

Daniel P. Petrylak, MD, on Urothelial Cancer: Phase II Trial Analysis of Sacituzumab Govitecan-hziy in Metastatic Disease

Daniel P. Petrylak, MD, of the Yale Cancer Center, discusses a primary phase II analysis of the TROPHY-U-01 study, cohort 2, which evaluated sacituzumab govitecan-hziy in platinum-ineligible patients with metastatic urothelial cancer that progressed after prior checkpoint inhibitor therapy. (Abstract 520).

Advertisement

Advertisement




Advertisement